PMID- 22706443
OWN - NLM
STAT- MEDLINE
DCOM- 20130317
LR  - 20211021
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 31
IP  - 9
DP  - 2012 Sep
TI  - The effects of extracorporeal photochemotherapy on T cell activation and 
      regulatory mechanisms in patients with systemic sclerosis.
PG  - 1293-9
LID - 10.1007/s10067-012-2000-x [doi]
AB  - In the study, we investigated the influence of extracorporeal photochemotherapy 
      (ECP) on lymphocyte activation and cell death by determining CD95, Annexin V, 
      CD69 and human leukocyte antigen (HLA)-DR expression on circulating T and B cells 
      in systemic sclerosis (SSc) patients and assessed their changes after ECP 
      therapies. Moreover, we evaluated the relationship between lymphocyte activation 
      and the observed changes in immunoregulatory functions following ECP treatments. 
      We enrolled 19 SSc patients, who received 12 ECP treatments in total. Blood 
      samples were taken prior to the first therapy and 6 weeks after each cycle. 
      Samples were also obtained from 16 healthy controls. Lymphocyte subgroups were 
      quantified by flow cytometry. Initially, patients had higher numbers and 
      percentages of peripheral CD95(+) T cells, but not CD95(+) B cells, compared to 
      control values. After ECP treatments, values of CD95(+) T cells decreased and 
      became similar to controls. Annexin V expression on T and B cells did not change 
      during the therapy. We observed a significant negative correlation between the 
      changes in percentages of peripheral CD95(+) T cells and CD4(+)CD25(+) Treg 
      cells. Although neither early-activated (CD69(+)) nor late-activated (HLA-DR+) T 
      lymphocytes showed significant changes after ECP, clear negative correlations 
      developed between them and the functional ability of CD4(+)CD25(+) Treg cells 
      after the last treatment. Our results indicate that the initial increase of 
      CD95(+) expression in SSc presumably reflects a physiological response to the 
      pronounced autoimmune processes, which can be effectively attenuated by the 
      restoration of regulative T cell numbers and functions as the result of ECP 
      therapy.
FAU - Papp, Gabor
AU  - Papp G
AD  - Division of Clinical Immunology, 3rd Department of Medicine, Medical and Health 
      Science Center, University of Debrecen, Moricz Zs. str. 22, 4032 Debrecen, 
      Hungary.
FAU - Barath, Sandor
AU  - Barath S
FAU - Szegedi, Andrea
AU  - Szegedi A
FAU - Szodoray, Peter
AU  - Szodoray P
FAU - Zeher, Margit
AU  - Zeher M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120616
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Annexin A5)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD3 Complex)
RN  - 0 (CD69 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Lectins, C-Type)
RN  - 0 (fas Receptor)
SB  - IM
MH  - Aged
MH  - Annexin A5/metabolism
MH  - Antigens, CD/biosynthesis
MH  - Antigens, Differentiation, T-Lymphocyte/biosynthesis
MH  - B-Lymphocytes/metabolism
MH  - CD3 Complex/biosynthesis
MH  - CD4-Positive T-Lymphocytes/cytology
MH  - Case-Control Studies
MH  - Female
MH  - HLA-DR Antigens/metabolism
MH  - Humans
MH  - Immune System
MH  - Lectins, C-Type/biosynthesis
MH  - *Lymphocyte Activation
MH  - Male
MH  - Middle Aged
MH  - Photopheresis/*methods
MH  - Scleroderma, Systemic/*therapy
MH  - T-Lymphocytes/*cytology/metabolism
MH  - fas Receptor/biosynthesis
EDAT- 2012/06/19 06:00
MHDA- 2013/03/19 06:00
CRDT- 2012/06/19 06:00
PHST- 2012/02/12 00:00 [received]
PHST- 2012/05/11 00:00 [accepted]
PHST- 2012/04/11 00:00 [revised]
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2013/03/19 06:00 [medline]
AID - 10.1007/s10067-012-2000-x [doi]
PST - ppublish
SO  - Clin Rheumatol. 2012 Sep;31(9):1293-9. doi: 10.1007/s10067-012-2000-x. Epub 2012 
      Jun 16.